v3.26.1
Schedule of Significant Expense Categories (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Total revenues $ 190,099 $ 622,849 $ 309,496 $ 716,713
Other research and development programs 2,041,389 2,136,769 4,805,782 3,198,341
Non-program expenses [1] 873,833 735,511 1,861,478 1,736,128
Personnel costs 1,042,353 1,028,142 2,204,264 2,112,907
Stock-based compensation 58,145 65,205 123,543 136,207
Total segment operating income (loss) (2,842,246) (2,404,353) (6,691,711) (4,494,538)
Other income (loss) [2] 219,651 198,637 397,222 423,949
Net income (loss) (2,622,595) (2,205,716) (6,294,489) (4,070,589)
Reportable Segment [Member] | Lead Clinical Candidate [Member]        
Segment Reporting [Line Items]        
Other research and development programs [3] 1,040,859 1,042,929 2,798,028 1,049,621
Reportable Segment [Member] | Other Research and Development Programs [Member]        
Segment Reporting [Line Items]        
Other research and development programs [3] $ 17,155 $ 155,415 $ 13,894 $ 176,388
[1] Includes general and administrative expenses, information technology, infrastructure, facilities, intellectual property, and legal and professional fees.
[2] Includes interest income and income tax expense.
[3] Includes external research and development expenses.